Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
Abstract Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patien...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
BMC
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/6fe58de71bfe4ffa81cf84773b662752 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|